The real-world safety and efficacy of sacituzumab govitecan (SG) against metastatic triple-negative breast cancer.
Triveni scores $115m to expand immunology pipeline – Pharmaceutical Technology
TRIV-573 is a preclinical bispecific antibody designed to target KLK5/7 and interleukin IL-13. Credits: Kmpzzz / Shutterstock. Triveni Bio has secured $115m in a Series